Sumitomo Mitsui DS Asset Management Company Ltd lifted its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 1.0% during the fourth quarter, Holdings Channel reports. The institutional investor owned 577,158 shares of the company’s stock after acquiring an additional 5,947 shares during the quarter. Johnson & Johnson makes up approximately 0.9% of Sumitomo Mitsui DS Asset Management Company Ltd’s investment portfolio, making the stock its 19th biggest position. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Johnson & Johnson were worth $119,443,000 at the end of the most recent quarter.
Other hedge funds have also recently made changes to their positions in the company. Cresta Advisors Ltd. purchased a new stake in shares of Johnson & Johnson in the 4th quarter worth approximately $26,000. McIlrath & Eck LLC increased its holdings in shares of Johnson & Johnson by 34.6% during the fourth quarter. McIlrath & Eck LLC now owns 727 shares of the company’s stock valued at $150,000 after acquiring an additional 187 shares in the last quarter. RNC Capital Management LLC raised its position in shares of Johnson & Johnson by 0.9% in the 4th quarter. RNC Capital Management LLC now owns 277,515 shares of the company’s stock worth $57,432,000 after purchasing an additional 2,540 shares during the last quarter. Morse Asset Management Inc grew its position in Johnson & Johnson by 2.4% during the 4th quarter. Morse Asset Management Inc now owns 19,224 shares of the company’s stock valued at $3,978,000 after purchasing an additional 450 shares during the last quarter. Finally, Christine Messmer PC purchased a new position in Johnson & Johnson in the fourth quarter worth about $416,000. 69.55% of the stock is owned by institutional investors.
Insider Activity at Johnson & Johnson
In other Johnson & Johnson news, EVP Timothy Schmid sold 22,623 shares of the stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total value of $5,527,477.59. Following the completion of the sale, the executive vice president owned 26,769 shares in the company, valued at approximately $6,540,469.77. This represents a 45.80% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Vanessa Broadhurst sold 6,197 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total value of $1,508,287.83. Following the sale, the executive vice president directly owned 23,003 shares in the company, valued at approximately $5,598,700.17. This represents a 21.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 30,142 shares of company stock worth $7,360,528 in the last ninety days. Insiders own 0.16% of the company’s stock.
Johnson & Johnson Trading Down 1.0%
Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its earnings results on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, topping analysts’ consensus estimates of $2.68 by $0.02. The company had revenue of $24.06 billion for the quarter, compared to analysts’ expectations of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.Johnson & Johnson’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same period last year, the firm earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, equities analysts anticipate that Johnson & Johnson will post 11.57 earnings per share for the current year.
Johnson & Johnson Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th will be paid a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date is Tuesday, May 26th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.30. Johnson & Johnson’s dividend payout ratio (DPR) is 60.12%.
Analyst Upgrades and Downgrades
JNJ has been the subject of several analyst reports. Citigroup raised their price target on shares of Johnson & Johnson from $274.00 to $285.00 and gave the company a “buy” rating in a research report on Tuesday, April 7th. Morgan Stanley set a $283.00 price target on Johnson & Johnson in a research note on Wednesday, April 15th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $265.00 price objective on shares of Johnson & Johnson in a report on Wednesday, April 15th. Loop Capital set a $220.00 price target on shares of Johnson & Johnson in a report on Tuesday, January 27th. Finally, Leerink Partners boosted their price objective on shares of Johnson & Johnson from $232.00 to $252.00 and gave the company a “market perform” rating in a report on Wednesday, April 15th. Eighteen investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $252.48.
Johnson & Johnson News Roundup
Here are the key news stories impacting Johnson & Johnson this week:
- Positive Sentiment: Oncology sales continue to drive growth — J&J reported strong oncology momentum (Darzalex, Erleada and recent launches) with double‑digit oncology sales growth and management reiterating an aggressive cancer revenue ambition toward long‑term targets. Darzalex, Erleada & New Drugs Keep J&J’s Oncology Engine Charged in Q1
- Positive Sentiment: Ottava surgical robot hit endpoints in a pivotal bariatric study, supporting MedTech commercialization prospects and an expanded addressable market for JNJ’s surgical‑robotics push. This outcome can underpin future revenue diversification. Johnson & Johnson says Ottava surgical robot met endpoints in pivotal bariatric surgery study
- Positive Sentiment: Corporate PR and patient‑engagement push — J&J launched the “Generation Fine” global campaign targeting depression care, which bolsters the company’s neuropsychiatry profile and may aid uptake if upcoming therapies get approvals. (Reputational/market positioning benefit.) Johnson & Johnson launches “Generation Fine”
- Neutral Sentiment: Pipeline expansion and R&D investments — J&J is advancing programs across immunology, MedTech and AI-enabled care; these longer‑term investments support future growth but carry typical development timelines and execution risk. Johnson And Johnson Expands Clinical Pipeline In Immunology MedTech And AI
- Negative Sentiment: Clinical setbacks weigh on sentiment — JNJ’s dual‑target antibody for IBD (JNJ‑4804) failed to meet its primary endpoint in Phase 2b, and related IBD program readouts were described as showing no meaningful improvement, raising doubts about near-term immunology launches. Johnson And Johnson Balances Mental Health Push With Mixed Pipeline Outlook
- Negative Sentiment: Independent coverage highlights a trial miss — reporting on the IBD trial outcome underscores execution risk and likely near‑term pressure on sentiment until clearer data or program pivots are provided. Johnson and Johnson advances IBD therapy, despite trial miss
Johnson & Johnson Profile
Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.
The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.
See Also
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
